Qiagen N.v. · NYSE:QGEN
Qiagen — Commerzbank Corporate Conference 2020
23 slides from Qiagen's conference presentation, Sep 21, 2020
Slide 1: Investor Handout Q3 2020
Investor Handout Q3 2020 Sample to Insight
Slide 2: Even stronger dynamic and innovative portfolio to unlock valuable molecular insights
Even stronger dynamic and innovative portfolio to unlock valuable molecular insights Sample Technologies Assay Technologies Academia How can we achieve scientific breakthroughs even faster? • Sample collection and stabilization • PCR and NGS kits containing • DNA/RNA/protein purification kits reagen
Slide 3: Addressing the continuum from basic research to clinical healthcare
Addressing the continuum from basic research to clinical healthcare Our Sample to Insight solutions Our Customers 2019 sales by product portfolio 2019 sales by customer class ~32% Academia / Applied Testing ~$1.5bn ~89% ~48% ~$1.5bn ~52% ~11% Consumables, Molecular Life Sciences Instruments (incl. s
Slide 4: Global presence in the most attractive developed and emerging markets
Global presence in the most attractive developed and emerging markets 2019 sales by geography Distribution Sollentuna partners ~32% Venlo Aarhus in over 60 Europe / Manchester Wroclaw Middle East / Toronto Stockach Hilden countries Beverly Milan Seoul Africa Paris Frederick Ankara Beijing Boston Bar
Slide 5: Emerging from a period of change with strong growth prospects and a focused strategy
Emerging from a period of change with strong growth prospects and a focused strategy Addressing large market opportunities in molecular research and testing • COVID-19 has dramatically changed industry growth dynamics such as decentralizing testing • Anticipating a longer-term increase in the utilit
Slide 6: Implementing key initiatives to target dynamic opportunities in a growing molecular market
Implementing key initiatives to target dynamic opportunities in a growing molecular market Support global Strengthen excellence Enter the digital PCR Accelerate Extend leadership in response to the in sample market with QIAcuity commercialization of tuberculosis (TB) COVID-19 pandemic technologies l
Slide 7: Initiatives to direct focus onto key drivers to accelerate portfolio growth
Initiatives to direct focus onto key drivers to accelerate portfolo growth Life Sciences Molecular Diagnostics Sample to Insight solutions Academic / Applied testing / Pharma Clinical healthcare COVID-19 solutions Sample Technologies In progress QIAcuity dPCR in 2021 QIAstat-Dx and NeuMoDx QuantiFER
Slide 8: Unprecedented demand for viral testing and research solutions
Unprecedented demand for viral testing and research solutions RNA sample Integrated PCR OEM components Dedicated extraction kits and antibody tests for other suppliers research solutions Manually or for use • QIAstat-Dx: Reagents purchased Tools for research on QIAGEN Syndromic PCR by other companie
Slide 9: Strengthening our excellence in Sample Technologies
Strengthening our excellence in Sample Technologies Build on strong position with a rapidly growing installed base of instruments • High demand for RNA extraction since start of the pandemic • Shift to increased utility of automation for COVID-19 testing • Sales of non-COVID-19 related sample prepar
Slide 10: Building on leading position in latent TB testing
Building on leading position in latent TB testing Market share expanding with rapid conversion of skin tests to modern IGRA testing • Current demand affected by revenue shift to COVID-19 testing QuantiFERON • Launch of QFT-Access for low-resource high disease burden areas planned for H2 2020 Market
Slide 11: Set to fully acquire NeuMoDx in H2 2020
Set to fully acquire NeuMoDx in H2 2020 (1) Significant market opportunity for fully integrated PCR-based platforms • Accelerated placement rate in response to COVID-19 testing demand • Expanded menu now totals 13 CE-IVD tests • Multi-plex respiratory test (Influenza, RSV, SARS-C0V-2) set for launch
Slide 12: Increased placements setting up solid base for long term utilization
Increased placements setting up solid base for long term utilization Syndromic testing platform with unparalleled ease-of-use • Accelerated placement rate in response to COVID-19 testing demand • Expanding use in non-traditional testing sites (e.g. cruise ships, athletic teams, corporate sites) • Si
Slide 13: Launching innovative technology into growing digital PCR market
Launching innovative technology into growing digital PCR market Novel differentiated technology allows potential conversion of quantitative PCR market • Planned launch in H2 2020 • Strong pipeline of >1,500 customer leads QIAGEN digital PCR technology • Plans for significant expansion of assay portf
Slide 14: Q2 and H1 2020: Summary
Q2 and H1 2020: Summary 1 Q2 2020 results • Net sales of $443.3 million (+16% actual, +19% CER) Q2 and H1 net sales Q2 and H1 adjusted EPS(1) • Adjusted operating income of $159.9 million (+61%, 36% of (In $ millions, at actual rates) (In $ per share) sales) +50% CER • Diluted EPS $0.38; adjusted EP
Slide 15: Q3 and FY 2020: Outlook
Q3 and FY 2020: Outlook Demand for coronavirus testing products expected to continue Outlook – As of July 13, 2020 Q3 2020 FY 2020 Net sales growth (CER) ~ +16-21% ~ +15-18% Anticipated currency impact(1) ~ 0 to +1 p.p. ~ -1 p.p. Adj. diluted EPS (CER) ~$0.52-0.58 ~≥$2.00 Anticipated currency impact
Slide 16: Appendix
George Mason University in Fairfax, Virginia Appendix Sample to Insight
Slide 17: International leadership team with extensive industry experience
International leadership team with extensive industry experience Executive Committee Supervisory Board CEO Appointed Lawrence A. Rosen Appointed Appointed Appointed in March Chair ininAugust in August August Supervisory Board 2020 2020 Thierry Bernard 2020 2020 Joined 2015 Joined 2013 CFO Life Scien
Slide 18: Q2 and H1 2020: Financial review
Q2 and H1 2020: Financial review Second quarter First half (In $ millions, unless indicated) (Diluted EPS in $ per share) 2020 2019 Change 2020 2019 Change Net sales(1) 443.3 381.6 16% / 19% CER 815.3 730.3 12% / 14% CER Operating income 118.7 60.2 97% 186.0 101.3 84% Adjusted operating income 159.9
Slide 19: Q2 and H1 2020: Sales by product type, customer class and region
Q2 and H1 2020: Sales by product type, customer class and region Q2 2020 net sales: $443.3 million H1 2020 net sales: $815.3 million Sales % % CER % Sales % % CER % Sales by product type (In $ m) change change of sales (In $ m) change change of sales Consumables and related revenues $375 12% 14% 85%
Slide 20: 2020: Total net sales overview
2020: Total net sales overview Net sales by customer class (In $ millions at actual rates / Q1 2020 Q2 2020 Q3 2020 Q4 2020 YTD 2020 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Molecular Diagnostics 176 4% 7% 204 9% 12% 380 7% 9% Life Scien
Slide 21: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Six months ended Six months ended June 30, June 30, June 30, June 30, (In $ thousands) 2020 2019 (In $ thousands) 2020 2019 Cash flows from operating activities: Cash flows from financing activities: Net income 129,593 74,248 Repayment of long-term d
Slide 22: Abbreviations
Abbreviations Adj Adjusted EBV Epstein-Barr virus JPY Japan Yen RGQ Rotor-Gene Q ALK Anaplastic Lymphoma Kinase EGFR Epidermal Growth Factor Receptor KRAS Kirsten rat Sarcoma Viral Oncogene RNA Ribonucleic Acid AML1 Acute Lymphoblastic Leukemia EGM Emerging Growth Markets Homolog ROM Rupture of Feta
Slide 23: Your contacts
Your contacts John Gilardi Vice President Calendar Corporate Communications and IR Phone: +49 2103 29 11711 Q3 2020 results November 2020 +1 240 686 2222 Mobile: +49 152 018 11711 Q4 2020 results February 2020 E-mail: john.gilardi@qiagen.com Phoebe Loh Share information Director Investor Relations N